Guidelines for the management of nilotinib (Tasigna
<sup>®</sup>)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)



Printable version
Guidelines for the management of nilotinib (Tasigna ^®)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)
Bulletin du Cancer. Volume 97, Number 8, 997-1009, août 2010, Synthèse
Résumé Texte intégral
Author(s) : G Étienne, B Milpied, D Réa, F Rigal-Huguet, M Tulliez, F-E Nicolini
Summary : Nilotinib (Tasigna ^®) is a second-generation BCR-ABL kinase inhibitor, recently introduced and used for the treatment of chronic or accelerated phase CML patients, intolerant or resistant to imatinib. This treatment represents and important step forward for the disease control of such patients but can lead to side effects, sometimes serious, which can limit its optimal use. We propose here some guidelines that might be of help in daily practice, in order to manage properly these side effects.
Keywords : CML, imatinib, nilotinib, TKI2, side effects

Guidelines for the management of nilotinib (Tasigna ®)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)